The assessment of replication success based on relative effect size (Q65581): Difference between revisions

From MaRDI portal
Importer (talk | contribs)
Changed an Item
Normalize DOI.
 
(3 intermediate revisions by 3 users not shown)
Property / DOI
 
Property / DOI: 10.1214/21-aoas1502 / rank
Normal rank
 
Property / cites work
 
Property / cites work: Sampling and Bayes' Inference in Scientific Modelling and Robustness / rank
 
Normal rank
Property / cites work
 
Property / cites work: The Well-Calibrated Bayesian / rank
 
Normal rank
Property / cites work
 
Property / cites work: Why should clinicians care about Bayesian methods? (With discussions and response) / rank
 
Normal rank
Property / cites work
 
Property / cites work: Introduction to Randomized Controlled Clinical Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesianly justifiable and relevant frequency calculations for the applied statistician / rank
 
Normal rank
Property / cites work
 
Property / cites work: Statistical Issues in Drug Development / rank
 
Normal rank
Property / DOI
 
Property / DOI: 10.1214/21-AOAS1502 / rank
 
Normal rank

Latest revision as of 20:34, 27 December 2024

scientific article
Language Label Description Also known as
English
The assessment of replication success based on relative effect size
scientific article

    Statements

    16
    0 references
    2
    0 references
    1 June 2022
    0 references
    14 July 2022
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    The assessment of replication success based on relative effect size (English)
    0 references
    power
    0 references
    replication studies
    0 references
    sceptical \(p\)-value
    0 references
    shrinkage
    0 references
    two-trials rule
    0 references
    type-I error rate
    0 references

    Identifiers